OncoMatch/Clinical Trials/NCT05722405
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Is NCT05722405 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Ixazomib plus low-dose lenalidomide and Ixazomib for multiple myeloma.
Treatment: Ixazomib plus low-dose lenalidomide · Ixazomib — Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CKS1B amplification
Required: FGFR3 fusion
Required: MAF fusion
Required: MAFB fusion
Required: TP53 deletion
Required: TP53 mutation
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Must have received: VRD regimen (bortezomib, lenalidomide, dexamethasone) induction and consolidation (bortezomib, lenalidomide, dexamethasone) — induction and consolidation
After induction and consolidation of the VRD regimen
Lab requirements
Kidney function
creatinine clearance (as estimated by cockcroft-gault) ≥ 60 ml/min (except for abnormal renal function due to multiple myeloma)
Liver function
serum alt and ast below 2.5 times the upper limit of normal; total bilirubin below 1.5 times the upper limit of normal
Cardiac function
cardiac ejection fraction ≥ 50%, no pericardial effusion confirmed by echocardiography, no clinically significant electrocardiographic findings
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05722405 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received VRD regimen (bortezomib, lenalidomide, dexamethasone) induction and consolidation.
Does this trial require CKS1B?
Yes, CKS1B amplification is a required biomarker for enrollment.
Does this trial require FGFR3?
Yes, FGFR3 fusion is a required biomarker for enrollment.
Does this trial require MAF?
Yes, MAF fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify